ADHD Therapeutics Market Analysis and Global Forecast to 2023

Market Overview:

At its core, ADHD is a disorder that makes it difficult for the person to pay attention, keep still, and control one’s impulses. While it is normal for children to have difficulty paying attention and staying still, people with ADHD never grow out of these symptoms and remain in that state well into adulthood. This can cause difficulty in school, as an inability to pay attention can result in the person falling behind in schoolwork, as well as at home, as people with ADHD tend to be very impulsive and forgetful. Daydreaming excessively, forgetting things, and making careless mistakes that could have been avoided simply by paying attention are considered to be classic symptoms of ADHD. Increasing awareness regarding ADHD is the primary driver for the global ADHD therapeutics market over the forecast period, as many parents still remain unaware of the condition, let alone of the possibility of curing it through medication.

The growth of the ADHD Therapeutics Market is primarily driven by the increasing usage of additives and preservatives in children’s diet, evolving lifestyles and changing value systems impact the quality of births, growing adoption of diagnostic guidelines with minimal threshold for diagnosis of ADHD in regions like South America and Europe, and prevalence of the disorder among children between the age group of 4 to 17 years.

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by three primary symptoms: inattention, hyperactivity, and impulsivity. The causes of ADHD are not well understood, but genetic factors are assumed to play a role in the development of the disorder. Exposure to toxins at a young age and brain injuries are also seen as contributing factors towards the development of ADHD.

Competitive Landscape:

·         Eli Lilly and Company

·         Concordia International Corp

·         NEOS Therapeutics Inc

·         Highland Therapeutics Inc

·         Pfizer Inc

·         Novartis AGNoven Pharmaceuticals Inc

·         Janssen Global Services LLC

·         Shire

·         Teva Pharmaceutical

Market Segmentation:

·         The global ADHD therapeutics market has been segmented in terms of distribution channels and drug types.

·         By distribution channel, the market comprises pharmacies, research laboratories, hospitals, clinics, and others.

·         By drug types, the market divides into non-stimulants and stimulants.

Regional Analysis:

Geographically, the global ADHD therapeutics market is segmented into North America, Europe, Asia Pacific (APAC), and Rest of the World. Of these, North America and Europe are likely to be the two largest regional markets for ADHD therapeutics over the forecast period. The presence of a highly developed neurological research network and easy availability of advanced therapeutics are the key drivers for the North America and Europe markets for ADHD therapeutics. The APAC ADHD therapeutics market has been a distant third in the global charts, as children with ADHD in APAC countries are often not treated for the same due to the absence of awareness about ADHD. However, this situation is changing, resulting in steady growth of the APAC ADHD therapeutics market